Challenges to orphan drugs access in Eastern Europe: The case of Bulgaria
- 1 November 2012
- journal article
- Published by Elsevier in Health Policy
- Vol. 108 (1) , 10-18
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Eliciting ethical and social values in health technology assessment: A participatory approachSocial Science & Medicine, 2011
- A comparative study of European rare disease and orphan drug marketsHealth Policy, 2010
- Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67BMJ, 2010
- Creating a global rare disease patient registry linked to a rare diseases biorepository database: Rare Disease-HUB (RD-HUB)Contemporary Clinical Trials, 2010
- Reference pricing of pharmaceuticalsJournal of Health Economics, 2007
- Does therapeutic reference pricing always result in cost-containment?: The Hungarian evidenceHealth Policy, 2007
- Assessing the economic challenges posed by orphan drugsInternational Journal of Technology Assessment in Health Care, 2007
- National health budgets for expensive orphan drugs: Gaucher disease in Israel as a modelBlood Cells, Molecules, and Diseases, 2006
- Orphan drugs revisitedQJM: An International Journal of Medicine, 2006
- Orphan drugs and the NHS: should we value rarity?BMJ, 2005